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Chagas disease or American trypanosomiasis is, together with geohelminths, the neglected disease that causes 
more loss of years of healthy life due to disability in Latin America. Chagas disease, as determined by the factors and 
determinants, shows that different contexts require different actions, preventing new cases or reducing the burden 
of disease. Control strategies must combine two general courses of action including prevention of transmission to 
prevent the occurrence of new cases (these measures are cost effective), as well as opportune diagnosis and treat-
ment of infected individuals in order to prevent the clinical evolution of the disease and to allow them to recuperate 
their health. All actions should be implemented as fully as possible and with an integrated way, to maximise the 
impact. Chagas disease cannot be eradicated due because of the demonstrated existence of infected wild triatomines 
in permanent contact with domestic cycles and it contributes to the occurrence of at least few new cases. However, 
it is possible to interrupt the transmission of Trypanosoma cruzi in a large territory and to eliminate Chagas disease 
as a public health problem with a dramatic reduction of burden of the disease.
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Chagas disease or American trypanosomiasis is, 
together with geohelminths, the neglected disease that 
causes more loss of years of healthy life due to disability 
in Latin America (Hotez et al. 2008).
Trypanosoma cruzi, its causative agent, can be trans-
mitted by different ways: vector (through triatomines), 
blood (through uncontrolled blood transfusions and organ 
donations, congenitally, by sharing needles among intra-
venous drug users, exceptionally through laboratory acci-
dents or surgical interventions with contaminated material) 
or oral (through food contaminated with faeces of infected 
vectors) (WHO 2002). The endemic area for vector-borne 
transmission extends from the southern United States of 
America (USA) to southern Argentina and Chile. Blood 
transmission can occur anywhere in the world where peo-
ple are infected and there are no screening strategies for 
blood or organ donors. The oral way has been described 
mainly, but not exclusively, in the Amazon Region.
The disease affects between seven-eight million 
people in the Americas (OPS 2006). It is estimated that 
between 20-30% of patients with infection will present 
some kind of clinical evidence (cardiac, digestive, neu-
rological or mixed) (WHO 2002).
The Pan American Health Organization (PAHO) has 
reviewed possibilities of different levels of control for 
several neglected diseases related with poverty. These 
diseases include Chagas disease among others like lym-
phatic filariasis, onchocerciasis, schistosomiasis, tra-
choma, soil-transmitted helminth, leprosy, congenital 
syphilis, among others. The discussion makes differ-
ences between different level of geographical distribu-
tion such as sub national, country or regional levels and 
levels of control possible to reach. Other discussion is 
which levels of control could be reached like eradica-
tion: as global and permanent incidence of zero due to 
deliberate actions, suspension of surveillance and con-
trol, control, reducing the burden of disease at certain 
levels of magnitude that would be defined, and elimina-
tion, zero incidence in a geographical area due to de-
liberate actions, requiring continued surveillance and 
control measures (OPS 2009a).
The aim of this review is to describe the current sta-
tus of Chagas disease control and the goal. We reviewed 
the evidence supporting the use of different strategies for 
control of Chagas disease. In this regard, a MEDLINE 
search was conducted, using the term “Chagas disease” 
with the subheadings, “control”, “diagnosis,” “prognosis,” 
“treatment”. No restrictions regarding year, language or 
country of publication were applied. Recent guidelines as 
well as ongoing and unpublished studies were also identi-
fied by consulting researchers and experts in the field.
Epidemiologic components
 
Modes of transmission and distribution factors - 
Various scenarios should be considered when trying to 
understand the transmission dynamics of T. cruzi. The 
emergence of transmission of T. cruzi and the main-
tenance cycle of Chagas disease involve a diversity of 
elements. There is diversity in vector species, their be-
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haviours and biotopes (Fig. 1), there is diversity in the 
lineage of the parasite (Zingales et al. 2012), diversity in 
its wild and human hosts, in their potential susceptibility 
to infection and in their response and there is also diver-
sity in the behaviours of the people infected and their 
social environment, generating a variety of risk or pro-
tection scenarios for the various forms of transmission.
The conjunction of this diversity creates some specific 
scenarios that must be taken into account when making a 
diagnosis of the situation and designing control strategies 
to prevent transmission or mitigate the existing damage.
Regarding the determinants related to the vector and 
its behaviour, we could consider scenarios where the 
main vector is exclusively domestic and introduced, as 
in the case of Rhodnius prolixus in Costa Rica, which 
could be eliminated (Hashimoto & Schofield 2012). Sce-
narios in which the main vector is essentially domestic, 
but not exclusively (as it can be found in wild niches 
close to homes), with the consequent risk of the reintro-
duction of this and other species, as in the case of Tria-
toma infestans in the phytogeographic region of South 
America’s Gran Chaco (constituted by geographical 
areas of Argentina, Bolivia and Paraguay) (Ceballos et 
al. 2011). Scenarios where the main vector is exclusively 
peridomestic in peridomestic and wild environments, as 
in the case of Triatoma dimidiata in Mexico, with the 
consequent difficulty of intervening to control its repro-
duction niche (Pacheco-Tucuch et al. 2012).
A different context is that of vector and oral trans-
mission, which is mainly associated with the presence 
of infected vectors that can contaminate food (Shikanai-
Yasuda & Carvalho 2012).
The conditions for food contamination with in-
fected vectors in the Amazon Region to become a risk 
of oral transmission of T. cruzi are partly the jungle 
environment where the infected triatomines reproduce 
and survive and which forms the domestic landscape in 
which the inhabitants of that region prepare and con-
sume their food (OPS 2009b).
T. cruzi is genetically diverse and understanding the 
population structure of this parasite is critical due to its 
association with transmission and disease cycles. Cur-
rently, T. cruzi is divided into six discrete typing units 
(DTUs), TcI-TcVI, with different prevalence according 
to the geographic region. DTUs TcI are prevalent in 
domestic settings, which have a higher risk for vector 
transmission, in northern South America and Central 
America, while DTUs TcII, V and VI are prevalent in 
southern South America (Zingales et al. 2012). The au-
thors that made this description concluded that major 
advances in the understanding of the pathogenicity and 
epidemiologic characteristics of these parasites can be 
expected in the next decade from the comparative analy-
sis of the genomes of several DTU strains (Zingales et 
al. 2012). However, potential differences with respect to 
the performance of diagnostic methods and therapeutic 
responses must be considered.
To all the above, we must add the prominent role 
played by social factors, which determine the behaviour 
of the people and their living conditions. Unfavourable 
geographical and political phenomena that prevent peo-
ple from living under decent conditions play a funda-
mental role in determining the risk of vector infestation 
in human habitats and the consequent risk of becoming 
infected through these routes. Thus, people’s behaviour 
can create situations of risk or protection. For example, 
a study conducted in 1984 in South America’s Gran 
Chaco region (Termas de Río Hondo, Santiago del Es-
tero, Argentina), in which there was no vector control 
or recent insecticide treatments at the time of the study, 
analysed the factors associated with the presence of 
infection in children. The combination of the presence 
of hiding places for vectors within the houses (cracked 
walls and thatched roofs), having more than two dogs or 
cats, animals sleeping in the bedrooms and peridomestic 
structures (sheds, pens etc.) close to the bedrooms were 
associated with an infection rate in children between 
five-14 years of age of 36.4%, while families in the same 
area where these same factors were absent had infection 
rates in children of the same age of 7.7%. Given that no 
vector control with insecticides was a factor in both cas-
es, the presence of environmental and behavioural fac-
tors posed a significant risk for acquiring the infection 
through vector transmission (Chuit et al. 2001).
The routes of transmission by blood are not condi-
tioned by environmental factors, as in the case of vector 
and oral transmission, but almost exclusively by socio-
demographic determinants associated with the migration 
of people. The risk of transmission by blood exists where 
Fig. 1: distribution of main species of Trypanosoma cruzi transmission 
vectors. This map was provided by Dr R Salvatella, Pan American 
Health Organization, Uruguay. 
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there are infected persons, the main factor to consider 
when planning public health interventions being the 
amount of infected people in a locality, whether or not 
the area suffers from triatomine infestation and vector 
transmission. Thus, in areas where no conditions exist 
for vector transmission (absence of vectors), but where 
there is intense immigration of people from an area with 
vector transmission, there may be a risk of transmission 
by blood that requires the implementation of measures 
to control transmission through these routes, such as 
screening of blood and organ donors and monitoring of 
pregnant women and newborns from women infected 
with T. cruzi (Mallimaci et al. 2001, 2010).
Prevention and control activities
Control strategies must combine two general courses 
of action including prevention of transmission to prevent 
the occurrence of new cases (these measures are cost effec-
tive) (Vazquez-Prokopec et al. 2009), as well as opportune 
diagnosis and treatment of infected individuals in order to 
allow them to recuperate their health, when possible, to 
provide comfort to the patient and to their family and com-
munity and to break the chain of transmission by blood by 
reducing the amount of parasites in donors and mothers 
(Sosa-Estani et al. 2012). It must be noted that reducing 
the burden of the disease on society would lead to a conse-
quent reduction in health-care spending (Lee et al. 2013).
Evolution of intervention strategies for control - In-
tervention strategies for the control of insect vectors were 
designed and implemented in the 50s and 60s and for the 
control of transmission by transfusion in the 60s and 70s, 
respectively. The pioneers in implementing these strategies 
were Venezuela, Brazil and Argentina (OPS 2002). Strat-
egies for control of congenital transmission began to be 
implemented in the 80s; while it still cannot be prevented, 
it can be controlled by early diagnosis and timely treatment 
of children with congenital infection (Blanco et al. 2000).
The chronology described above occurred in sev-
eral countries in the Americas, with different times of 
implementation and different levels of efficacy. There 
also countries without formally established programs for 
controlling the transmission of T. cruzi. Since the end of 
the 90s, other regions such as North America, Europe 
and Australia have launched research projects and some 
countries have implemented programs for controlling a 
specific route of transmission (the only one in the area), 
such as universal screening of blood donors in the USA, 
or, as in Spain, of donors coming from regions of en-
demic vector transmission (WHO 2002).
The practices for taking care of people infected with 
this disease have evolved from the time when Carlos Cha-
gas first described it; they currently include health team 
interventions and care guides (MS 2012a), which have 
been implemented in very different ways in different 
endemic countries. Only in the mid-90s some countries 
started to implement the practice of detecting infected 
children and providing them with etiological treatment 
as part of a number of strategic actions for controlling the 
disease (OPS 2002). This is now part of the protocol used 
by endemic countries, which have institutional control 
programs through which they certify the interruption of 
vector transmission by demonstrating the absence of in-
fection in children less than five years of age. A certifica-
tion of the interruption of transmission is complemented 
by the absence of the vector, low domestic infestation (< 
1%) and no reported cases of acute vector Chagas, among 
other indicators. The status reached of interruption is 
characterised by a sustained surveillance after intensive 
activities of control of vectors (OPS 2002). A review con-
clude that the combination of spray activities for control 
of focus of infestation and the community participation 
should become a strategic component of Chagas disease 
surveillance (Abad-Franch et al. 2011).
The activities to prevent transmission of T. cruzi by 
transfusion are based on the implementation of blood 
bank control. These strategies started in 70s by 2005 did 
not reached an adequate rate of implementation in Latin 
America (Schmunis & Cruz 2005), but it was improved 
during last decade and more recently these programs 
were implemented in nonendemic countries (Requena-
Méndez et al. 2014). Fig. 2 shows the progress of the in-
terruption of vector transmission in the countries of the 
Americas. Only recently has emphasis been placed on 
the comprehensive care of infected people in any stage 
of the infection (MS 2012b) as essential to the goal of 
eliminating Chagas disease as a public health problem 
(Sosa-Estani 2012, Sosa-Estani et al. 2012).
Achieved effect - The sum of the measures for preven-
tion of transmission have had different a different effect 
depending on the possibility of implementing interven-
tions. The factors on which this depends include: (i) the 
political and technical decision to implement the strategies 
with sufficient evidence of efficacy [some examples that 
demonstrate the feasibility of the various factors described 
in (i) are the success in interrupting vector and blood trans-
mission, with total or partial geographic coverage in some 
countries, such as Argentina, Brazil, Chile, Uruguay and 
some others in Central America (Fig. 2)], (ii) the complex-
ity of the scenario in which the intervention takes place 
[examples of (ii) could correspond to specific sub-regions, 
such as the complexity of determinants in the Amazon Re-
gion that cause outbreaks of oral transmission] and (iii) the 
lack of tools or strategies or insufficient evidence of ef-
ficacy [examples of (iii) could be special situations such as 
the occurrence of pockets of triatomines resistant to insec-
ticides approved for vector control] (Germano et al. 2012).
The measures implemented in recent decades have 
had an effect, as confirmed by the World Health Orga-
nization (WHO) when describing that the number of in-
fected people decreased from 30 million in 1990 to 15 
million in March 2006 (OPS 2006). However, these es-
timates may have methodological shortcomings in their 
calculations and may not allow us to make an accurate 
assessment due to their high potential margin of error. It 
is also clear that the various control measures that have 
been systematically carried out since the formal estab-
lishment of control programs for Chagas in endemic 
countries at the start of the 60s have served to prevent 
new cases in many countries in the Americas. However, 
the diversity of socioepidemiological scenarios and im-
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plementation status of control programs has meant that 
while the main routes of transmission of public health 
interest (vector and blood) have been successfully inter-
rupted in some regions, new cases involving these routes 
of transmission are still occurring in other regions.
The control of vector and blood transmission of T. 
cruzi clearly improved the transmission profile in Latin 
America. Some specific examples of these progress in dif-
ferent geographical dimension are the control in the state 
of São Paulo, Brazil, which started by 70s with continu-
ous surveillance and high impact avoiding new cases by 
vector transmission for several decades (Carvalho et al. 
2011). On the other hand in Central America (Guatemala, 
El Salvador, Honduras and Nicaragua) an example of in-
teraction between international cooperation by the Japan 
International Cooperation Agency, Japan, official control 
programs of the countries involved and community or-
ganised could reach a high level of control of transmission. 
This model highlighted for the success: the knowledge for 
what actions should be taken to control the disease, the 
competence to obtain resources and capacity to implement 
control actions, the channels for the institutional network 
and infrastructure and the control of the technical and ad-
ministrative management (Hanada & Hashimoto 2014).
A very important issue to warranty the success of the 
Chagas disease programs is to implement evaluations 
programs of each activity, control quality, to monitoring 
its efficacy. These aspects were recently reviewed by a 
PAHO/WHO group of experts and in addition were dis-
cussed that subjects involving sustainability, coverage, 
financing and quality of the program must be taken into 
account in each evaluation.
Fig. 2: status control vector transmission in the Americas. Source: Pan American Health Organization (paho.org/hq/index.php?option=com_t
opics&view=article&id=10&Itemid=40743).
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Also it is necessary to offer process such as social, 
administrative and political issues involving an official 
declaration of disease elimination, considering the pos-
sible positive and negative points that can arise from this 
declaration taking into account gaps and needs for this 
goal. Some examples of the new scenario and the role of 
different actors are the recent constitution of the Federa-
tion of People Affected for Chagas disease (findechagas.
com/), the coalitions of nongovernmental organisations 
(NGOs) (web.mundosano.org/novedades/mundo-sano-
hoy/lanzan-una-coalicion-global-para-luchar-contra-la-
enfermedad-de-chagas/) in same case with the industry 
(unitingtocombatntds.org/resource/london-declaration), 
forum for research (dndial.org/es/doencas-negligencia-
das/enfermedad-de-chagas/plataformachagas.html), the 
constitution or revision of a national plan with political 
support and international declaration of WHO Assembly.
Beyond the measurement of progress, several ques-
tions still remain, which can only be answered by fur-
ther scientific research. At present, there is the need of 
designing and implementing a quality control system for 
the supply of domestic insecticides and for making ac-
curate estimates of the effect of control measures on the 
incidence of new infections.
Considering the response of health systems to the re-
emergence of another infection caused by insects, den-
gue, it is surprising how fast they reacted, despite the 
fact that several programs for control of vector-borne 
diseases have started to be dissolved. In some regions of 
Latin America, this fast response was made possible by 
the strong influence of the control initiatives carried out 
by the PAHO of the WHO. Although we cannot quantify 
this influence, it can be said that it is a cultural influence 
generated by the initiatives. The case of the reemergence 
of the dengue virus and that of the emergence of the chi-
kungunya virus, both transmitted by the Aedes genus, 
calls into question whether it is not time to strengthen 
the control programs and the scientific and technical 
training of the members of those programs in order to 
make them more effective and less costly in the context 
of the current challenges.
Having achieved the desired effect of interrupting 
the transmission of a disease, a major challenge is to 
achieve sustainable control measures to prevent a rees-
tablishment of transmission, as happened with dengue 
and malaria in the Americas (Dick et al. 2012). Some 
of the current strategies aimed to achieve sustainability 
involve empowering local governments and promoting 
community mobilisation and participation through or-
ganised communities and NGOs.
The establishment of integrated programs con-
structed collectively allows proposing strategies that 
address as many determinants as possible for the con-
trol of Chagas disease. As an example, the recently re-
vised National Program for Control of Chagas disease 
in Argentina, implemented between 2010-2016, consists 
of five strategic lines: (i) strategies for the prevention 
and control of vector transmission (vector control and 
surveillance, resistance monitoring, improvement of the 
environment - domestic and peridomestic), (ii) strategies 
for the prevention and control of nonvector transmission, 
particularly of transmission by blood, (iii) strategies for 
the control of congenital infection, (iv) strategies for the 
control of acute and chronic infection in carriers of T. 
cruzi and (v) general and transversal strategies for the 
whole program including strengthening of the political 
dimension, strengthening of the resources of the national 
and local programs for Chagas, social communication 
and community participation, assessment and monitor-
ing of the program (MS 2012b).
These nationwide programs should consider particu-
lar situations, mainly related to vulnerable communi-
ties, such as care in indigenous communities where the 
perception and acceptability of the strategies should be 
approached with particular caution. This based on the 
evidence of the failure of interventions in these commu-
nities due to several factors, one of them being the use 
of standard procedures which in these populations may 
cause a kind of culture shock (Sosa-Estani et al. 2009a, 
Dell’arciprete et al. 2014).
In 2010, the WHO estimated the existence of seven-
eight million people infected with T. cruzi distributed 
throughout the world. The region of the Americas, par-
ticularly Latin America, where those with the highest 
proportion of infected people, being endemic areas for 
vector transmission the most efficient type of transmis-
sion. However, the phenomenon of human migration has 
created scenarios in need of attention in other regions of 
the world such as Europe, Japan and Australia, mainly 
with respect to the diagnosis and treatment of infected 
people to prevent and control congenital transmission 
and transmission by contaminated blood (WHO 2013).
There is limited information about the effect of health 
care activities in infected people on the overall activities 
of prevention and control. However, two fundamental 
concepts must be taken into account, either with evi-
dence or when suggesting a hypothesis. The first is the 
direct effect that timely cares with early interventions 
have on the quality of life of the patients, with the conse-
quent reduction of the burden of the disease by prevent-
ing or stopping its progression (secondary and tertiary 
prevention) (Sosa-Estani et al. 2012). The second con-
cept is that indicating a trypanocidal treatment, which 
has proven effective in eliminating or reducing the para-
sitic infection, modifies the population parasitaemia, 
with consequential benefits. These benefits may include 
changing the natural history of the disease by produc-
ing less severe clinical chronic forms and/or decreasing 
the influence of parasitaemia (Sosa-Estani et al. 2009b) 
as a determining factor in the occurrence of congenital 
transmission (Bua et al. 2012, Howard et al. 2014).
Care of people and levels of prevention 
There are guidelines advising regarding management 
and care of people infected with T. cruzi. A precocious 
and adequate clinical management is required to all 
acute or chronic cases. A timely and adequate clinical, 
pharmacological and chirurgical management if neces-
sary is essential. The specific treatment has to be con-
sidered currently among other therapies (WHO 2002). 
For instance, timely management of initial arrhythmia, 
heart failure or megaesophagus is fundamental to avoid 
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or delay the appearance of severe and irreversible situa-
tions, according several longitudinal studies have dem-
onstrated (Viotti et al. 2005, Rassi Jr et al. 2006).
A challenge to each health system is how to imple-
ment the activities to provide an adequate care of people 
infected. There is a diversity of system, but all of them 
must to warrant a care with quality. There is a consen-
sus that most of patients can to be care in the primary 
health care level and to be included into the schedule of 
national control programs.
The role of etiological treatment for T. cruzi infec-
tion on several levels of prevention in public health - 
The etiological treatment allows for actions on several 
levels of public health prevention. Previous studies pro-
vide evidences useful for applying health care strategies 
in control programs in several countries. When a high 
number of people can get diagnosis, treatment and cure, 
it generates a new scenario for the future reduction of the 
burden of the disease.
Primary prevention level - If the goal is to prevent 
the occurrence of new infections, etiological treatment 
could have an indirect effect when applied to children 
and young people. Curing children and women in repro-
ductive age would prevent future events of congenital T. 
cruzi transmission (Sosa-Estani et al. 2009a, Fabbro et 
al. 2014). In addition, blood and organ donors would in-
crease if infected people are treated. Unfortunately, the 
effectiveness of the etiological treatment with respect to 
these primary prevention indications remains unknown, 
although it can be assumed to be at least equal to the 
seronegativisation rates observed in some studies. An-
other strategy would be to obtain a feasible treatment for 
pregnant women, such as that used for human immuno-
deficiency virus (HIV) infection, to prevent congenital 
transmission during pregnancy. However, safe drugs are 
necessary for this strategy.
Etiological treatment in cases of accidents with ma-
terial contaminated with parasites or with blood samples 
of patients infected with T. cruzi could also be consid-
ered as an indication for primary prevention. In fact, the 
treatment is not strictly prophylactic, as it is not possible 
to prevent infections, but the infection can be aborted 
immediately after the accident with a timely treatment 
and an appropriate concentration of specific drugs (Her-
waldt 2001). Recent results show the benefit, in terms 
of primary prevention, of treating girls and women of 
childbearing age before pregnancy, preventing the con-
genital transmission of T. cruzi to children born after-
wards (Sosa-Estani et al. 2009a, Fabbro et al. 2014).
Secondary prevention level - If prevention activi-
ties cannot prevent infection in children, curing infected 
children is still possible by prescribing etiological treat-
ment (Cerisola 1977, Moya et al. 1985, Russomando et 
al. 1998, Sosa-Estani et al. 2009b, Bern 2011). In this 
regard, etiological treatment should be indicated when 
damages from cardiac or digestive disease are not 
strongly present in children. This is the best opportunity 
to get seronegativisation and avoid disease, thus preserv-
ing social, mental and physical health into adulthood (de 
Oliveira Jr et al. 2006, Villa et al. 2007).
National control programs have been implemented 
in more and more Latin-American countries since 1994. 
They consist of the screening of children populations as a 
regular strategy providing early diagnosis and treatment 
(Silveira 2002). The positive effect of curing infected chil-
dren detected by serological screening must be assessed 
by taking into account the number of infected people, the 
transmission, evolution and burden of Chagas disease, so 
that it becomes possible to analyse the usefulness of serol-
ogy as an indicator of action against the vector.
Another indication for etiological treatment in second-
ary prevention is to prevent the reactivation of a chronic 
infection. Immunosuppression due to the application of 
immunosuppressive therapies (Diez et al. 2007) or HIV/
acquired immune deficiency syndrome (Cordova et al. 
2008) increases the risk of reactivation in patients with 
chronic infection. Even though the effectiveness of etio-
logical treatment for the clinical control of reactivation 
episodes has been demonstrated, it is necessary to gather 
evidence as to whether preventive treatment is effective in 
patients with no signs of clinical reactivation and with ab-
normal immunological parameters (Nishioka 2000). In this 
regard, some protocols recommend treating organ donors 
infected with T. cruzi to reduce the risk of transmission 
by transplant (Altclas et al. 2005). In this case, treatment 
should be considered as a primary prevention action.
Tertiary prevention level - The use of etiological 
treatment against T. cruzi infection in order to reduce the 
negative effect of established disease is being evaluated 
using two randomised clinical trials for assessing its ef-
ficacy in patients with ongoing cardiac disease (Reyes & 
Vallejo 2005, Riarte et al. 2005, Marin-Neto et al. 2008). 
These trials are appraising the efficacy of benznidazole 
for preventing the progression of cardiac disease.
Several observational studies have been published 
showing the effects of etiological treatment on patients 
infected with T. cruzi with respect to preventing the pro-
gression of chronic chagasic cardiomyopathy (Sosa-Es-
tani et al. 2009b). These studies achieved quality of evi-
dence type II and strength of recommendation B and C. 
The prognosis of patients with heart failure or advanced 
stages of chagasic cardiomyopathy is poor (Rassi Jr et al. 
2006), but similar to that of other patients who develop 
heart failure. Since the disease is chronic and heart dam-
age develops over decades, it is very important to rec-
ognise the factors that determine the progression of the 
disease in the early stages (Viotti et al. 2005). The evo-
lution of knowledges addressed to the current scenario 
with a new paradigm regarding benefit of trypanocide 
treatment (Viotti et al. 2014). The etiological treatment 
should be considered as a protective factor in the model 
of the physiopathology of chagasic cardiomyopathy.
As mentioned above, the effectiveness of etiological 
treatment in the control of reactivation episodes has been 
proved, showing recovery from severe manifestations of 
reactivation such as meningoencephalitis, myocarditis, 
panniculitis etc. (Diez et al. 2007, Cordova et al. 2008).
Based on our current understanding of the disease, 
there is a consensus that every patient infected with T. 
cruzi must (children) or should be treated (adults). Treat-
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ment can cure infection and reduce or prevent the pro-
gression of Chagas-related heart disease/cardiomyopa-
thy. The current evidence of the benefits and limitations 
of etiological treatment based on clinical and implemen-
tation research help prioritise primary health care strat-
egies, focusing on completing the course of treatment, 
rather than demonstrating serological negativisation.
Incorporating etiological treatment as a public health 
strategy useful at the primary, secondary and tertiary pre-
vention levels is essential to reduce the burden of the disease 
and to eliminate Chagas disease as a public health issue.
There are guidelines advising regarding management 
and care of people infected with T. cruzi. A precocious 
and adequate clinical management is required to all 
acute or chronic cases. A timely and adequate clinical, 
pharmacological and chirurgical management if neces-
sary is essential. The specific treatment has to be con-
sidered currently among other therapies (WHO 2002). 
For instance, timely management of initial arrhythmia, 
heart failure or megaesophagus is fundamental to avoid 
or delay the appearance of severe and irreversible situa-
tions, according several longitudinal studies have dem-
onstrated (Viotti et al. 2005, Rassi Jr et al. 2006).
The medical care all over Latin America have dif-
ferent systems with subsystems and it must to have into 
account to resolve access to diagnosis and treatment, 
coverage, referential system, medical expertise, among 
others considerations. This is a new goal for an integrat-
ed Chagas disease control programs, including the care 
of people infected as formal objective and activities.
Control models and their effect - Based on the above, 
we can graph three intervention models and their expected 
effect on the evolution of the number of infected people.
The Fig. 3 defines three scenarios according to the 
intervention models and three times (baseline, medium 
and long term regarding time lapsed). These three sce-
narios are described just as a concept and not defined 
through a mathematical model. The first scenario where 
no intervention against the vector is carried out and 
vector transmission continues unabated generates an 
increase in the number of infected people. The second 
scenario is where only primary prevention actions are 
implemented, such as vector control and control of blood 
and organ donors. These actions achieve a progressive 
reduction of the number of infected people, but without 
Fig. 3: combined effect of prevention and care for people in the control of Chagas disease.
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care for infected people they remain infected for the 
rest of their lives; due to the phenomenon of population 
parasitaemia and migration, the risk of transmission by 
blood would increase. Finally, the third scenario consid-
ers primary prevention actions in conjunction with care 
of infected people, including etiological treatment. This 
combination can reduce the number of people infected 
with T. cruzi in a shorter time.
The implementation of actions with sufficient evidence 
of efficacy carried out in an integrated manner throughout 
the country is a challenge of political and technical decision-
making. The proof of success in some communities should 
be a stimulus/incitation for communities with similar sce-
narios where these actions have not been implemented.
The field of research is oriented towards finding al-
ternatives when the tools/strategies used stopped work-
ing or are unavailable. Thus, the research priorities for 
the present situation have been defined different in dis-
cussion forums, trying to find the best way of achiev-
ing an efficient implementation of control actions for 
the prevention of new cases and for taking care of those 
already infected (Dujardin et al. 2010).
Chagas disease cannot be eradicated due to the mul-
tiple scenarios that contribute to the occurrence of new 
cases and mainly because of the demonstrated existence 
of infected wild triatomines in permanent contact with 
domestic cycles. However, it is possible to interrupt the 
transmission of T. cruzi in a large territory, we have 
discussed before the complexity of dynamic of vector 
transmission to avoid new cases and having expectance 
to eradicate or eliminate this disease. Measures avail-
able of prevention of Chagas disease can reach high level 
of control due to total interruption of transmission by 
transfusion, total interruption of vector transmission in 
large areas and partial interruption or control in areas 
like Amazon Region and adequate level of coverage of 
timely diagnoses and treatment of people infected. The 
hypothesis is that in the future always will remain just 
few new cases, but the conjunction of the previous goal 
described will allow to eliminate Chagas disease as a 
public health problem. In this sense a cut-off point of 
magnitude of prevalence or incidences of people infect-
ed and its burden disease to decide when Chagas disease 
is not a public health problem has to be developed.
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